Clinical trial
A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)
NCT00542386 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled Multiple Fixed-dose Study of MCI-196 Versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia (Incorporating Two Parallel High Dose Groups)
- Lead sponsor
- Tanabe Pharma Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2007
- Completion date
- November 30, 2009
- Enrollment
- 642 (actual)
- Sites
- 73
Conditions
As the registry lists them; a condition with its own page is linked.
chronic kidney disease, dialysis, dyslipidemia, hyperphosphatemia